Extract
We read with great interest the meta-analysis recently published in the European Respiratory Journal by Yang et al. [1] concerning the risk of major adverse cardiovascular events (MACE) in COPD patients with dual bronchodilatation (long-acting β2 agonist (LABA)/long-acting muscarinic antagonist (LAMA)) or triple therapy (LABA/LAMA/inhaled corticosteroids (ICS)) compared with LABA/ICS.
Abstract
COPD patients had an increased cardiovascular risk. The impact of triple therapy on cardiovascular events is controversial compared to its clinical benefits. https://bit.ly/3OSRTmZ
Footnotes
Conflict of interest: P. Martinez-Camblor has nothing to disclose. P. Almagro reports grants and lecture honoraria from Chiesi and GSK, and advisory board participation and receipt of materials from Chiesi, outside the submitted work.
- Received November 18, 2022.
- Accepted November 28, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org